Damora Therapeutics (DMRA) Cash from Investing Activities (2021 - 2024)

Damora Therapeutics (DMRA) has 4 years of Cash from Investing Activities data on file, last reported at $6.0 million in Q2 2024.

• For the quarter ending Q2 2024, Cash from Investing Activities rose 94.11% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2024 stood at $11.6 million (down 47.83% YoY), and the FY2025 full-year result was -$17.4 million, down 249.13% from the prior year.
• Cash from Investing Activities for Q2 2024 stood at $6.0 million, up from $5.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $14.4 million in Q4 2021 and bottomed at -$74.6 million in Q1 2021.
• The 4-year median for Cash from Investing Activities is $5.8 million (2024), against an average of -$120285.7.
• The widest annual swing landed in 2022, when Cash from Investing Activities plunged 101.0%; it then jumped 6160.78% in 2023.
• A 4-year view of Cash from Investing Activities shows it stood at $14.4 million in 2021, then declined by 0.57% to $14.3 million in 2022, then slumped by 33.15% to $9.6 million in 2023, then sank by 37.37% to $6.0 million in 2024.
• The last three Cash from Investing Activities figures came in at $6.0 million (Q2 2024), $5.6 million (Q1 2024), and $9.6 million (Q4 2023), per Business Quant data.

Peer Comparison